Table 1 Cerebrospinal fluid findings following treatment initiation with nusinersen and tofersen. T1: treatment-naive; T2: month 6 of nusinersen treatment/month 2 of tofersen treatment (after completed loading phases); T3: month 54 of nusinersen treatment/month 9 of tofersen treatment
Patient 1 – SMA: | Patient 2 – SOD1-ALS: | ||||||
|---|---|---|---|---|---|---|---|
Reference values | T1 | T2 | T3 | T1 | T2 | T3 | |
Leucocyte count (MPt/L) | < 5 | 3 | 4 | 1 | 1 | 3 | 21 |
Protein (mg/L) | 150–450 | 249 | 262 | 214 | 483 | 764 | 1235 |
Albumin (mg/L) | < 350 | 129 | 137 | 134 | 268 | 558 | 879 |
Albumin ratio (x10− 3) | (4 + Age/15) | 3.37 | 3.58 | 3.41 | 5.60 | 12.85 | 18.65 |
IgG (mg/L) IgG synthesis (%) | 10–30 negative | 14.1 0.0 | 12.8 0.0 | 12.53 0.0 | 44.48 1.5 | 69.09 0.0 | 115.63 0.0 |
IgA (mg/L) IgA synthesis (%) | 1–3 negative | 1.29 0.0 | 1.58 0.0 | 1.74 0.0 | 5.81 0.0 | 10.78 0.0 | 17.94 0.0 |
IgM (mg/L) IgM synthesis (%) | 0.5–1.5 negative | < 0.5 0.0 | < 0.5 0.0 | < 0.12 0.0 | 0.33 0.0 | 1.82 0.0 | 12.26 62.6 |
OCBs (CSF/Serum) | negative | Type 4 | Type 4 | Type 1 | Type 4 | Type 1 | Type 4 |
Lymphocytes (%) | 50–90 | 93 | 88 | 97 | 94 | 85 | 85 |
Monocytes (%) Macrophages with unspecified inclusions | 10–50 none | 6 – | 9 + | 1 + | 3 – | 9 + | 10 + |